ACTIVE

BIOPHARM

Financial year 2025 · Closed on 30/09/2025

Net result-43,5 k €-168,8 %over 1 year

Revenue10,3 M €+12,6 %over 1 year

Equity5,4 M €-0,8 %over 1 year

Identity

Source · BCE/KBO

BIOPHARM is a Public limited company incorporated in 1989. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Kortenberg.

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0438.547.292
Incorporation: 10/10/1989
Legal form: Public limited company
Registered office: Stationstraat 8
3070 Kortenberg · FlandreSee on map
Contributed capital: 3 453 330,00 €
Latest accounts: 30/09/2025

Activities (NACE)

47730Dispensing chemist in specialised stores· main 47730Dispensing chemist in specialised stores 52310Warehousing and support activities for transportation

Joint committees (1)

Contacts

4 public details availableLog in to view

Signals

Solid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 22 filings

Trend over 19 financial years

	2025		2024		2023		2022		2021
Income statement
Revenue	10,3 M €	+12.6%	9,2 M €	+4.7%	8,8 M €	+9.0%	8 M €	+8.8%	7,4 M €
EBITDA	683,2 k €	+8.2%	631,3 k €	+38.9%	454,5 k €	+22.2%	371,9 k €	+1.5%	366,4 k €
Operating result	188,2 k €	+21.7%	154,6 k €	+668%	20,1 k €	+173%	-27,7 k €	-368%	10,4 k €
Net result	-43,5 k €	-169%	-16,2 k €	+78.1%	-73,9 k €	-4.8%	-70,5 k €	+4.9%	-74,2 k €
Balance sheet
Equity	5,4 M €	-0.8%	5,4 M €	-0.3%	5,4 M €	-1.3%	5,5 M €	-1.3%	5,6 M €
Total assets	12 M €	+1.8%	11,8 M €	+1.1%	11,7 M €	-0.8%	11,8 M €	+5.9%	11,1 M €
Cash	8,1 k €		–		–		3,2 k €	-38.8%	5,3 k €
Debts	6,1 M €	+5.0%	5,8 M €	+3.2%	5,6 M €	+0.3%	5,6 M €	+15.8%	4,8 M €
Other
Workforce	–		–		–		–		–

Valuation

Indicative valuation

As an indication, this company is worth

between 250 k€ and 500 k€

See the valuation

Board of directors

Source · NBB, accounts to 30/09/2025

2 active · 8 ended

Active mandates

Carine Knapen

Mandate

Active

Theo Schrevens

Mandate

Active

Ended mandates

Caspieca

Mandate · 0860.588.255

Represented by Ann Van De Casteele

Ended

Caspieca

Mandate · 0860.588.255

Represented by Ann Van De Catseele

Ended

Caspieca

Mandate · 0860.588.255

Ended

Caspieca

Mandate · 0860.588.255

Ended

Other companies at this address

Stationstraat 8 3070 Kortenberg

Company	CBE no.
SoBiVet● Active	0880.969.737

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Micro model	Micro model	Micro model	Micro model	Abridged model	Abridged model
Start of the financial year	01/10/2024	01/10/2023	01/10/2022	01/10/2021	01/10/2020	01/10/2019
Closing of the financial year	30/09/2025	30/09/2024	30/09/2023	30/09/2022	30/09/2021	30/09/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	30/04/2026	30/04/2025	31/03/2024	30/03/2023	13/04/2022	30/04/2021
General meeting	31/03/2026	30/04/2025	28/03/2024	23/03/2023	25/03/2022	25/03/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 22 filings

Model	Closing	General meeting	Filed	Language	Document
Micro model	30/09/2025	31/03/2026	30/04/2026	Dutch	PDF
Micro model	30/09/2024	30/04/2025	30/04/2025	Dutch	PDF
Micro model	30/09/2023	28/03/2024	31/03/2024	Dutch	PDF
Micro model	30/09/2022	23/03/2023	30/03/2023	Dutch	PDF
Abridged model	30/09/2021	25/03/2022	13/04/2022	Dutch	PDF
Abridged model	30/09/2020	25/03/2021	30/04/2021	Dutch	PDF
Abridged model	30/09/2019	26/03/2020	14/05/2020	Dutch	PDF
Abridged model	30/09/2018	28/03/2019	29/04/2019	Dutch	PDF
Abridged model	30/09/2017	29/03/2018	18/05/2018	Dutch	PDF
Abridged model	30/09/2016	23/03/2017	27/04/2017	Dutch	PDF
Abridged model	30/09/2015	24/03/2016	31/03/2016	Dutch	PDF
Abridged model	30/09/2014	26/03/2015	13/04/2015	Dutch	PDF
Abridged modelCorrection	30/09/2013	13/03/2014	20/07/2014	Dutch	PDF
Abridged model	30/09/2013	13/03/2014	07/05/2014	Dutch	PDF
Abridged model	30/09/2012	14/03/2013	30/04/2013	Dutch	PDF
Abridged model	30/09/2011	22/03/2012	18/04/2012	Dutch	PDF
Abridged modelCorrection	30/09/2010	13/05/2011	21/09/2011	Dutch	PDF
Abridged model	30/09/2010	13/05/2011	17/05/2011	Dutch	PDF
Abridged model	30/09/2009	15/05/2010	18/05/2010	Dutch	PDF
Abridged model	30/09/2008	24/04/2009	29/04/2009	Dutch	PDF
Abridged model	30/09/2007	25/04/2008	29/04/2008	Dutch	PDF
Abridged model	30/09/2006	27/12/2006	02/02/2007	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 250 k€ and 500 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 30/09/2025

2 active · 8 ended

Active mandates

Carine Knapen

Mandate

Active

Theo Schrevens

Mandate

Active

Ended mandates

Caspieca

Mandate · 0860.588.255

Represented by Ann Van De Casteele

Ended

Caspieca

Mandate · 0860.588.255

Represented by Ann Van De Catseele

Ended

Caspieca

Mandate · 0860.588.255

Ended

Caspieca

Mandate · 0860.588.255

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates21/10/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates10/12/2019
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares04/02/2019
KAPITAAL - AANDELEN
PDF
Mandates27/02/2014
ONTSLAGEN - BENOEMINGEN
PDF
Restructuring24/10/2007
RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
PDF
Restructuring27/08/2007
DIVERSEN - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
PDF
Mandates13/11/2003
ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

2025
Annual accounts 2025-43,5 k €↓
2024
Annual accounts 2024-16,2 k €↑
2023
Annual accounts 2023-73,9 k €↓
2023
Name changeSoBiVet NV
2022
Annual accounts 2022-70,5 k €↑
2021
Annual accounts 2021-74,2 k €↑
2021
Name changeBiopharm Nv
2020
Annual accounts 2020-79 k €↓
2019
Annual accounts 2019-51 k €↓
2018
Annual accounts 201825,6 k €↑
2017
Annual accounts 201713,9 k €↑
2016
Annual accounts 20169,3 k €↓
2015
Annual accounts 201513,8 k €↑
2014
Annual accounts 201412,1 k €↑
2013
Annual accounts 20132 k €↓
2012
Annual accounts 2012115,1 k €↓
2011
Annual accounts 2011127,1 k €↑
2010
Annual accounts 20104,5 k €↑
2009
Annual accounts 20093,9 k €↓
2008
Annual accounts 200827,9 k €↑
2007
Annual accounts 20078,3 k €
10/10/1989
IncorporationPublic limited company

BIOPHARM

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline